Phuturdex › Diseases › Lipid metabolism disorder
Drugs in development · updated 30 October 2026
Lipid metabolism disorder: drugs in development
As of 30 October 2026 there are 5 active clinical trials (recruiting or ongoing, phases I–III) on 4 drugs for lipid metabolism disorder. 4 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Zodasiran | III | 1 | NCT07473843 |
| 4D-310 | I–II | 2 | NCT05629559 |
| FBX-101 | I–II | 1 | NCT05739643 |
| CTX310 | I | 1 | NCT07491172 |
Sorted by most advanced phase and number of active trials.
All 4 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Dyslipidemia 35 drugs
- Hyperlipidemia 26 drugs
- Hypercholesterolemia 21 drugs
- Hypertriglyceridemia 18 drugs
- Gaucher's disease 18 drugs
- Hyperlipoproteinemia Type II 12 drugs
- Fabry disease 10 drugs
- Cardiovascular disease 71 drugs
- Arterial hypertension 119 drugs
- Homozygous familial hypercholesterolemia 7 drugs
- Atherosclerosis 34 drugs
- Type 2 diabetes 171 drugs
Broader categories
- Nutritional and metabolic diseases 5 drugs
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities 4 drugs
- Metabolism, Inborn Errors 6 drugs
- Brain Diseases 23 drugs
- Inborn metabolic brain disease 3 drugs
- X-linked disease 8 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D052439 “Lipid Metabolism Disorders”.